Previous 10 | Next 10 |
Lexicon Pharmaceuticals (NASDAQ:LXRX) is trading ~11.8% higher in the pre-market after announcing a new analysis demonstrating the clinical benefits of diabetes therapy sotagliflozin in heart failure and blood glucose control. The pooled analysis was based on data from SOLOIST ...
Post hoc analysis of pooled clinical data from the SOLOIST and SCORED trials supporting benefit of sotagliflozin presented at the virtual American Heart Association Scientific Sessions 2021, including: Sotaglifozin significantly reduced total cardiovascular deaths, hospitaliza...
THE WOODLANDS, Texas, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that a new analysis of sotagliflozin results from the SOLOIST and SCORED Phase 3 outcomes studies will be presented at the virtual American Heart Association Scienti...
Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2021 Earnings Conference Call November 03, 2021, 05:00 PM ET Company Participants Chas Schultz - Executive Director of Corporate Communications & Patient Advocacy Lonnel Coats - President and Chief Executive Officer and Director Jeff Wade - Executiv...
Shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) are down 8% in after-hours trading even though the company's Q3 2021 earnings results beat expectations on GAAP EPS. Lexicon swung to a net loss in the quarter of $23.1M ($0.16 per share) from net income of $82.6M in the prior-year per...
THE WOODLANDS, Texas, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended September 30, 2021 and provided an update on key milestones. “We are on track for submission around year-end...
THE WOODLANDS, Texas, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its third quarter 2021 financial results on Wednesday, November 3, 2021 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m....
A list of 62 recent IPOs debuted on The Russell 2000 small-cap index after index provider FTSE Russell implemented its Q3 reconstitution. Following up on our previous article on recently-IPOd biotech stocks joining the index, in this article, we discuss another four biotechs ma...
THE WOODLANDS, Texas, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, Lexicon’s president and chief executive officer, will present virtually at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit o...
Vinco Ventures (NASDAQ:BBIG) +65%. Aterian (NASDAQ:ATER) +52%. Support.com (NASDAQ:SPRT) +45%. Affirm Holdings (NASDAQ:AFRM) +40% as Amazon to integrate pay-over-time into its cart Globalstar (NYSE:GSAT) +36% on report iPhone 13 may use satellite connectivity Katapult...
News, Short Squeeze, Breakout and More Instantly...
Lexicon Pharmaceuticals Inc. Company Name:
LXRX Stock Symbol:
NASDAQ Market:
Lexicon Pharmaceuticals Inc. Website:
THE WOODLANDS, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2024 financial results on Thursday, August 1, 2024 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00...
Launch Preparations Actively Underway; Launch Planned for Early 2025 Lexicon Seeks Approval for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease THE WOODLANDS, Texas, July 16, 20...
New analysis of the pivotal Phase 3 SOLOIST-WHF trial provides additional evidence of positive economic impact on hospitals participating in various alternative payment models (APM) Findings consistent with two peer-reviewed studies published in June 2024 THE WOODLANDS, Texa...